Numbers Don't Suffer: Reconciling Improved Biomarkers with Declining Patient Well-Being

There is a particular kind of clinical dissonance that experienced prescribers know well, even if they rarely name it outright. The patient sitting across from them looks tired, moves slowly, and speaks with the measured cadence of someone conserving energy. Yet the chart tells a different story: LDL is down, HbA1c has normalized, blood pressure sits comfortably within guideline targets. By every measurable standard, the regimen is working. So why does the patient keep saying they feel worse?

This tension—between what metrics report and what patients experience—is not a failure of data collection. It is a structural feature of how modern pharmacotherapy is designed, studied, and evaluated. Understanding it is not optional for clinicians who aim to prescribe with genuine precision.

How Surrogate Endpoints Became the Language of Therapeutic Success

The reliance on biomarkers as proxies for health outcomes is deeply embedded in both regulatory science and clinical practice. Surrogate endpoints—cholesterol levels, glycated hemoglobin, glomerular filtration rate, ejection fraction—offer something that patient-reported outcomes cannot: consistency, objectivity, and statistical tractability. Regulatory agencies including the FDA have long accepted surrogate markers as the basis for drug approval, particularly when long-term outcome trials would be prohibitively expensive or time-consuming to conduct.

This framework has produced genuine advances. But it has also created a prescribing culture in which improving a number can quietly displace improving a person. When a statin brings LDL to target, when an SGLT2 inhibitor corrects glycemia, when a beta-blocker steadies a resting heart rate, the clinical impulse is to declare the intervention successful. Whether the patient can climb stairs without fatigue, maintain their work schedule, or sleep through the night often receives less structured attention.

The problem is not that biomarkers are uninformative. It is that they are incomplete—and that incompleteness carries real clinical consequences.

Recognizing the Gap Before It Becomes a Crisis

Quality-of-life deterioration under a technically optimized regimen rarely announces itself dramatically. More often, it accumulates gradually: a patient who was once engaged becomes passively compliant; someone previously motivated to exercise stops mentioning it; a caregiver reports that the patient seems "off" in ways that resist easy articulation. These signals are easy to miss in a fifteen-minute appointment structured around reviewing lab results.

Several drug classes are particularly associated with this pattern. Beta-blockers, while effective at controlling heart rate and reducing cardiovascular mortality, are well-documented contributors to fatigue, sexual dysfunction, and mood changes—side effects that patients may not volunteer and clinicians may not probe. Certain antiepileptics produce cognitive blunting that patients describe as feeling "foggy" or "slowed down," even when seizure frequency is well-controlled. Diuretics used in heart failure management can produce orthostatic symptoms, cramps, and electrolyte disturbances that undermine functional capacity even as they reduce fluid overload on imaging.

The pattern is consistent across therapeutic categories: the medication accomplishes its biochemical objective while simultaneously eroding some dimension of the patient's functional life. Because neither the patient nor the clinician has a shared vocabulary for this trade-off, it often goes unaddressed until it manifests as nonadherence.

A Structured Approach to Quality-of-Life Assessment in Routine Practice

Building a systematic check for functional deterioration into standard prescribing practice does not require lengthy consultations or complex instrumentation. Several validated tools are brief enough for routine clinical use. The Patient-Reported Outcomes Measurement Information System (PROMIS) global health scales, developed with NIH support, can be completed in under three minutes and capture physical, mental, and social dimensions of well-being. Disease-specific instruments—such as the Minnesota Living with Heart Failure Questionnaire or the Diabetes Distress Scale—offer more granular insight in relevant populations.

Beyond formal instruments, a small set of targeted questions can meaningfully shift the clinical conversation:

• "How has your energy level changed since we adjusted your medications?" This invites patients to connect their subjective experience to the treatment timeline without leading them toward a particular answer.
• "Are there activities you've stopped doing or found more difficult in the past few months?" Functional decline is often expressed through behavioral change before it surfaces as a complaint.
• "On a typical day, how do you feel compared to how you felt before we started this medication?" Global self-rated health is a surprisingly robust predictor of clinical outcomes and captures dimensions that disease-specific metrics miss.

Documenting these responses with the same rigor applied to laboratory values creates a longitudinal record of functional trajectory—one that can inform treatment adjustments before deterioration becomes entrenched.

Reassessing Treatment Goals When the Evidence and the Patient Diverge

When a patient's functional status is declining despite favorable biomarkers, the clinical imperative is not to dismiss the patient's experience or to abandon the medication uncritically. It is to reopen the goals-of-care conversation with appropriate depth.

This begins with distinguishing between treatment targets that are evidence-based for mortality and morbidity reduction versus those that are guideline-recommended but less robustly tied to outcomes that matter to the individual patient. An HbA1c of 6.5% may be the textbook target, but for a 78-year-old patient with limited functional reserve, the hypoglycemic episodes required to achieve it may impose greater harm than a target of 7.5% or 8.0% would. Similarly, aggressive blood pressure control in older adults has been associated with falls, syncope, and cognitive impairment—risks that must be weighed explicitly against the cardiovascular benefits that motivate treatment.

The 2023 American Geriatrics Society Beers Criteria and related deprescribing frameworks provide structured guidance for these reassessments, but the underlying principle applies across age groups: treatment goals should be individualized, revisited regularly, and explicitly calibrated to what the patient values most.

Communicating the Paradox to Patients and Colleagues

One of the underappreciated challenges in this space is linguistic. Patients who feel worse while their labs improve often doubt their own perception—they have been told, implicitly or explicitly, that the numbers are the truth. Clinicians who raise quality-of-life concerns with colleagues may encounter resistance from those who interpret any deviation from guideline targets as suboptimal care.

Clear, non-defensive communication in both directions is essential. With patients, framing the conversation around their stated priorities—"You told me that staying active and feeling sharp matter most to you. Let's talk about whether this regimen is actually supporting those goals"—validates their experience while grounding the discussion in clinical terms. With colleagues, presenting quality-of-life data alongside biomarker data signals that both dimensions are legitimate objects of clinical attention, not competing concerns.

Documentation practices matter here as well. Noting functional status, patient-reported symptoms, and the rationale for any deviation from standard targets creates a defensible, patient-centered clinical record.

Precision That Includes the Person

The promise of precision medicine is that treatment can be tailored to the individual rather than applied uniformly across a population. But that promise is only partially fulfilled when individualization stops at the genomic or biochemical level. True precision requires incorporating the patient's functional experience, their values, and the real-world consequences of the medications they take.

When a prescriber recognizes that a drug is winning on the lab report while losing in the patient's daily life, they are not identifying a failure of pharmacology. They are identifying an opportunity—to recalibrate, to communicate, and to prescribe with the kind of clinical judgment that numbers alone will never be able to supply.